» Articles » PMID: 39348269

Autoantibodies in Systemic Sclerosis Overlap Syndrome and Their Correlation with Organ Damage and Survival

Overview
Journal Ann Med
Publisher Informa Healthcare
Specialty General Medicine
Date 2024 Sep 30
PMID 39348269
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Systemic sclerosis (SSc) often overlaps with other autoimmune diseases. More complex autoantibody profiles may be observed in SSc overlap syndrome (SSc OS). To determine the clinical significance of autoantibodies in SSc OS and classify the patients more accurately for better disease assessments, we analysed the correlation between serological profiles, organ involvements and outcomes.

Methods: A retrospective cohort study was conducted in Peking University People's Hospital. Chi-square tests and analysis of variance were used to analyse univariate comparisons of clinical symptoms, organ involvement and laboratory indicators. Survival was evaluated using Cox proportional hazards model.

Results: Among 141 cases, anti-Ro-52 was the most common antibody, followed by anti-centromere antibody and anti-Scl-70 antibody. We analysed the correlation between autoantibodies and vital organ damage in SSc OS patients, and compared the differences across four SSc OS subgroups (SSc SLE, SSc RA, SSc PM/DM and SSc SS) to demonstrate the correlation between autoantibodies and clinical characteristics and organ damage. Cox regression analysis showed that scleroderma renal crisis (SRC) ( = .004) and pulmonary arterial hypertension (PH) ( = .010) were independent risk factors for survival.

Conclusions: Autoantibodies are associated with clinical features, organ involvement and prognosis in SSc OS patients. Anti-Scl-70 antibody is associated with interstitial lung disease (ILD) and SRC, while ACA is a protective factor of ILD. SRC and PH are risk factors associated with death.

Citing Articles

Cardiac Morpho-Functional Changes, Inflammation and Fibrosis in Systemic Sclerosis-A Pilot Study of a Tertiary Center Cohort.

Dorniak K, Gogulska Z, Viti A, Glinska A, Kulawiak-Galaska D, Fijalkowska J Diagnostics (Basel). 2025; 15(3).

PMID: 39941322 PMC: 11817609. DOI: 10.3390/diagnostics15030393.

References
1.
Rubio-Rivas M, Corbella X, Pestana-Fernandez M, Tolosa-Vilella C, Guillen-Del Castillo A, Colunga-Arguelles D . First clinical symptom as a prognostic factor in systemic sclerosis: results of a retrospective nationwide cohort study. Clin Rheumatol. 2017; 37(4):999-1009. DOI: 10.1007/s10067-017-3936-7. View

2.
Jantarat A, Muangchan C . Epidemiology and clinical characteristics of systemic sclerosis overlap syndrome (SSc-OS), and the factors significantly associated with SSc-OS in Thai patients with systemic sclerosis. Mod Rheumatol. 2021; 32(5):899-907. DOI: 10.1093/mr/roab079. View

3.
Mimori T, Akizuki M, Yamagata H, Inada S, Yoshida S, Homma M . Characterization of a high molecular weight acidic nuclear protein recognized by autoantibodies in sera from patients with polymyositis-scleroderma overlap. J Clin Invest. 1981; 68(3):611-20. PMC: 370841. DOI: 10.1172/jci110295. View

4.
Rubio-Rivas M, Royo C, Simeon C, Corbella X, Fonollosa V . Mortality and survival in systemic sclerosis: systematic review and meta-analysis. Semin Arthritis Rheum. 2014; 44(2):208-19. DOI: 10.1016/j.semarthrit.2014.05.010. View

5.
Butikofer L, Varisco P, Distler O, Kowal-Bielecka O, Allanore Y, Riemekasten G . ACE inhibitors in SSc patients display a risk factor for scleroderma renal crisis-a EUSTAR analysis. Arthritis Res Ther. 2020; 22(1):59. PMC: 7093969. DOI: 10.1186/s13075-020-2141-2. View